Search Results - David E Gerber

Refine Results
  1. 1
    Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report

    Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report by Amrit S. Gonugunta, Mitchell S. von Itzstein, David E. Gerber

    Published 2022-07-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Upfront Brain Treatments Followed by Lung Surgery Improves Survival for Stage IV Non-small Cell Lung Cancer Patients With Brain Metastases: A Large Cohort Analysis

    Upfront Brain Treatments Followed by Lung Surgery Improves Survival for Stage IV Non-small Cell Lung Cancer Patients With Brain Metastases: A Large Cohort Analysis by Xiaopeng He, Xiaopeng He, Shen Yin, Shen Yin, Hongyu Liu, Rong Lu, Kemp Kernstine, David E. Gerber, David E. Gerber, David E. Gerber, Yang Xie, Yang Xie, Yang Xie, Donghan M. Yang

    Published 2021-10-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC

    Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC by Heidi A. Hamann, PhD, David E. Gerber, MD

    Published 2022-09-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients?

    Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients? by Mitchell S. von Itzstein, David E. Gerber, John D. Minna

    Published 2020-10-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience.

    How have we diagnosed early-stage lung cancer without radiographic screening? A contemporary single-center experience. by Evelyn O Taiwo, Jeffrey T Yorio, Jingsheng Yan, David E Gerber

    Published 2012-01-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Acknowledging and addressing real-world challenges to treating immune-related adverse events

    Acknowledging and addressing real-world challenges to treating immune-related adverse events by Bonnie L Bermas, Mitchell S von Itzstein, David E Gerber, Alexa Meara

    Published 2024-07-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report

    Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report by David E. Gerber, MD, Melissa Mayer, RN, Jeffrey Gagan, MD, Mitchell S. von Itzstein, MD

    Published 2022-03-01
    Get full text
    Article
    Save to List
    Saved in:
  8. 8
    Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality?

    Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care qualit... by Mitchell S von Itzstein, Arjun Gupta, Kemp H Kernstine, Kristin C Mara, Sahil Khanna, David E Gerber

    Published 2020-01-01
    Get full text
    Article
    Save to List
    Saved in:
  9. 9
    Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage

    Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage by Elizabeth R. Zhang-Velten, MD, PhD, David E. Gerber, MD, Kenneth D. Westover, MD, PhD

    Published 2020-11-01
    Get full text
    Article
    Save to List
    Saved in:
  10. 10
    Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection

    Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection by Mitchell S. vonItzstein, Rong Lu, Kemp H. Kernstine, Ethan A. Halm, Shidan Wang, Yang Xie, David E. Gerber

    Published 2020-06-01
    Get full text
    Article
    Save to List
    Saved in:
  11. 11
    Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice

    Highly variable timing renders immunotherapy efficacy and toxicity impractical biomarkers of one another in clinical practice by Mitchell S. von Itzstein, Mitchell S. von Itzstein, Yuqiu Yang, Yiqing Wang, David Hsiehchen, Thomas Y. Sheffield, Farjana Fattah, Vinita Popat, Murtaza Ahmed, Jade Homsi, Jade Homsi, Jonathan E. Dowell, Jonathan E. Dowell, Sawsan Rashdan, Sawsan Rashdan, Jay Lohrey, Jay Lohrey, Hans J. Hammers, Hans J. Hammers, Randall S. Hughes, Randall S. Hughes, Tao Wang, Tao Wang, Yang Xie, Yang Xie, David E. Gerber, David E. Gerber, David E. Gerber

    Published 2024-04-01
    Get full text
    Article
    Save to List
    Saved in:
  12. 12
    Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report

    Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report by Shelby Edmondson, BA, Mitchell S. von Itzstein, MD, Brian Reys, MS, Melissa Mayer, BA, Jeffrey Gagan, MD, David E. Gerber, MD

    Published 2022-08-01
    Get full text
    Article
    Save to List
    Saved in:
  13. 13
    DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden

    DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden by David Hsiehchen, Antony Hsieh, Robert M. Samstein, Tianshi Lu, Muhammad S. Beg, David E. Gerber, Tao Wang, Luc G.T. Morris, Hao Zhu

    Published 2020-06-01
    Get full text
    Article
    Save to List
    Saved in:
  14. 14
    Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer

    Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer by Shetal A. Patel, David E. Gerber, Allison Deal, Kathe Douglas, Chad V. Pecot, Carrie Lee, Joan Schiller, Nirav Dhruva, Jared Weiss

    Published 2021-04-01
    Get full text
    Article
    Save to List
    Saved in:
  15. 15
    Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

    Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial by Caitlin C. Murphy, Hannah M. Fullington, David E. Gerber, Isaac Alex Bowman, Maneka Puligandla, Janice P. Dutcher, Robert S. DiPaola, Naomi B. Haas

    Published 2021-09-01
    Get full text
    Article
    Save to List
    Saved in:
  16. 16
    Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer

    Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer by Sandi L. Pruitt, David E. Gerber, Hong Zhu, Daniel F. Heitjan, Bhumika Maddineni, Danyi Xiong, Amit G. Singal, Anna Tavakkoli, Ethan A. Halm, Caitlin C. Murphy

    Published 2021-07-01
    Get full text
    Article
    Save to List
    Saved in:
  17. 17
    Distinct autoantibody profiles across checkpoint inhibitor types and toxicities

    Distinct autoantibody profiles across checkpoint inhibitor types and toxicities by Hong Mu-Mosley, Mitchell S. von Itzstein, Farjana Fattah, Jialiang Liu, Chengsong Zhu, Yang Xie, Edward K. Wakeland, Jason Y. Park, Brad S. Kahl, Catherine S. Diefenbach, David E. Gerber

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  18. 18
    Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids

    Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids by Ke Gong, Gao Guo, Nicole A. Beckley, Xiaoyao Yang, Yue Zhang, David E. Gerber, John D. Minna, Sandeep Burma, Dawen Zhao, Esra A. Akbay, Amyn A. Habib

    Published 2021-12-01
    Get full text
    Article
    Save to List
    Saved in:
  19. 19
    Use of artificial intelligence chatbots in clinical management of immune-related adverse events

    Use of artificial intelligence chatbots in clinical management of immune-related adverse events by Jarushka Naidoo, Igor Puzanov, Paolo A Ascierto, Marc S Ernstoff, Douglas B Johnson, Fei Ye, Mitchell S von Itzstein, David E Gerber, Benjamin Switzer, Aliyah Pabani, Hannah Burnette, Run Fan

    Published 2024-05-01
    Get full text
    Article
    Save to List
    Saved in:
  20. 20
    Association between immune-related adverse event timing and treatment outcomes

    Association between immune-related adverse event timing and treatment outcomes by David Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, Mitchell S. Von Itzstein, Alessio Cortellini, Biagio Ricciuti, Dwight H. Owen, Mehak Laharwal, Yukihiro Toi, Michael Burke, Yang Xie, David E. Gerber

    Published 2022-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: